Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial-Reference-Cited by-同舟云学术

Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial

Published:2018-02 Issue:4 Volume:121 Page:423-429
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Lee Cheol Hyun,Lee Jong-Young,Park Gyung-Min,Lee Seung-Whan,Kim Hyun-Sook,Choi Young Jin,Nam Chang-Wook,Cho Jang Hyun,Shin Won-Yong,Seo Jae Bin,Choi Si Wan,Lee Jae-Hwan,Min Pil-Ki,Her Sung-Ho,Lee Pil Hyung,Ahn Jung-Min,Park Duk-Woo,Kang Soo-Jin,Kim Young-Hak,Lee Cheol Whan,Park Seong-Wook,Park Seung-Jung

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor;Ikeda;Thromb Haemost,1999

2. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry);Lee;Am Heart J,2010

3. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis;Lee;J Am Coll Cardiol,2005

4. Coronary stent restenosis in patients treated with cilostazol;Douglas;Circulation,2005

5. A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison between mono vs dual vs triple antiplatelet therapy in patients with ischemic heart disease undergoing PCI, a network meta-analysis;Current Problems in Cardiology;2024-11

2. The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis;International Journal of Molecular Sciences;2024-02-23

3. Cilostazol induces vasorelaxation through the activation of the eNOS/NO/cGMP pathway, prostanoids, AMPK, PKC, potassium channels, and calcium channels;Prostaglandins & Other Lipid Mediators;2023-12

4. Monitoring antiplatelet therapy: where are we now?;Journal of Cardiovascular Medicine;2022-12-15

5. A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease;Journal of Personalized Medicine;2022-06-06